U.S. Electrical Stock News

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

We can readily understand why investors are attracted to unprofitable companies. For example, Telos ( NASDAQ:TLS...

Key Insights Institutions' substantial holdings in Voyager Therapeutics implies that they have significant influence...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Simpson Manufacturing Co., Inc. ( NYSE:SSD ), is not the largest company out there, but it saw a decent share price...

ICON (ICLR) has delivered solid earnings, growing its profits by 27.1% per year on average over the past five years, with the most recent year showing 11.2% earnings growth. Net profit margins improved to 9.8% from last year’s 8.6%, and future earnings are forecast to rise by 10.97% annually. Backed by these positive trends in earnings quality and sustained margin expansion, investors are looking at a company with underlying strength and favorable valuation signals. See our full analysis for...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Tesla (TSLA) reported a net profit margin of 5.3%, down from last year’s 13.3%, as the company saw negative earnings growth over the most recent year despite averaging 19.2% annual earnings growth over the past five years. Still, the outlook remains upbeat, with revenue forecast to rise 16.9% per year and earnings expected to surge by 36% annually, both easily outpacing broader US market averages. See our full analysis for Tesla. Up next, we’ll see how these results hold up against the major...

Reliance (NYSE:RS) posted net profit margins of 5.2%, down from 7.4% a year ago, highlighting a decrease in profitability. While the company’s earnings have grown at just 0.9% per year on average over the past five years, forecasts now call for earnings growth of 11.1% per year and revenue to expand by 3% annually. Recent margin compression and slower profit acceleration set the stage for investors to weigh the company’s high earnings quality and attractive dividend against shifting growth...

Origin Bancorp (NYSE:OBK) reported net profit margins of 20.5%, down from 23.5% a year ago. Earnings have risen at an annual rate of 3.7% over the past five years. Shares currently trade at $33.09, which is well below the company’s estimated fair value of $59.93. Looking ahead, OBK’s earnings are forecast to grow at 19.8% per year, which is above the broader US market expectation of 15.5% annual growth. However, with revenue growth projected to lag the market and margins coming under...

Coya Therapeutics, Inc. has completed a follow-on equity offering worth US$20,000,002, issuing 3,636,364 shares of common stock at US$5.50 per share. This capital raise signals the company’s focus on securing funding for continued development of its therapeutic programs and growth initiatives. With fresh capital in hand, we'll examine how the follow-on equity offering influences Coya Therapeutics' investment narrative and funding outlook. The end of cancer? These 27 emerging AI stocks are...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Oceaneering International (OII) reported a net profit margin of 8.2%, a healthy advance over last year’s 5.2%. Earnings have posted consistent gains, rising 70.9% year-over-year and growing at an annual pace of 81.4% over the past five years. Recent profitability metrics, together with a Price-To-Earnings Ratio of 10.3x that sits below both its peers and the broader industry average, highlight the quarter as another step in the company’s transition to high-quality earnings and perceived value...

If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? More often...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...

Major stock indexes in the United States recently ended lower as investors weighed earnings reports and ongoing U.S.-China trade tensions. In such a fluctuating market, penny stocks—despite their somewhat outdated moniker—remain a compelling area for investment, particularly when they are backed by solid financials. These smaller or newer companies can offer surprising value and potential for growth, making them worth considering for investors seeking hidden opportunities in quality stocks.

In October 2025, the U.S. stock market has been navigating a complex landscape marked by renewed U.S.-China trade tensions and mixed earnings reports, leading to declines in major indices such as the Nasdaq, Dow Jones Industrial Average, and S&P 500. Amidst this backdrop of uncertainty and fluctuating investor sentiment, identifying promising small-cap stocks can offer unique opportunities for those looking to uncover potential growth avenues in less-explored corners of the market.

As the U.S. stock market grapples with earnings reports and renewed U.S.-China trade tensions, major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 have ended lower. In such uncertain times, dividend stocks can offer a reliable income stream for investors seeking stability amidst market volatility.

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Visteon (VC) posted revenue growth forecasts of 4.8% per year, which lags the broader US market average of 10%. Net profit margin came in at 7.6%, slipping from last year’s 13.8%, while earnings are only expected to grow at 7.1% per year compared to the market’s 15.5% pace. Over the past five years, annual earnings grew quickly, but the most recent year saw earnings decline, and shares now trade at $110.22, notably below the company's fair value estimate of $157.77. With decent value metrics...

Earlier this week, Verastem Oncology announced promising preliminary data from the Phase 1/2a clinical trial of VS-7375, an oral KRAS G12D inhibitor, in patients with advanced KRAS G12D mutant solid tumors, along with the initiation of a combination cohort with cetuximab. These findings are significant, as there are currently no FDA-approved therapies specifically targeting KRAS G12D mutations in cancer, addressing a critical gap for patients with limited treatment options. We'll explore how...

Ventyx Biosciences (VTYX) is in the spotlight after announcing positive Phase 2 results for its oral drug, VTX3232, which targets obesity and cardiovascular risk factors. The trial reported a substantial drop in inflammation markers. See our latest analysis for Ventyx Biosciences. Ventyx’s positive trial news gave momentum a significant boost, with the share price leaping 135.7% in the past month and delivering a remarkable 208.4% year-to-date share price return. However, the three-year total...